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ABSTRACT 
Emulgel is one of the emerging topical drug delivery system for the delivery of hydrophobic drugs which overcome various 
disadvantages of ointments and creams such as greasiness and phase inversion.  
Etoricoxib is poorly aqueous soluble Non steroidal Anti-Inflammatory Drug (NSAID).  It is used in osteoarthritis, rheumatoid 
arthritis, acute gouty arthritis, ankylosing spondylitis, low back pain, acute postoperative pain, and primary dysmenorrheal. Its oral 
delivery is associated with greater chance of adverse effects or therapeutic failure and large amount of drug is lost in the vicinity of 
the target organ. Also oral administration of etoricoxib causes gastro-intestinal irritation. The aim of the present study was to 
develop an emulgel formulations using the gelling agent like Carbopol 934 and HPMC K4M with emulsifiers like Span 20 and 
Tween 20. Six emulgel formulations were developed and evaluated on different parameters like physical appearance, pH, 
viscosity, extrudability, drug content, spreadability, in-vitro diffusion studies, and skin irritation test. Best formulation of batch 
EG1 was further evaluated for stability study and anti-inflammatory activity in carrageenan induced rat paw edema. Anti-
inflammatory effect of formulation EG1 was compared with standard market product Indomethacin.  
Keywords: Anti-inflammatory effect, carrageenan, emulgel, etoricoxib,  gelling agent, hydrophobic. 
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INTRODUCTION 
Drug delivery via skin has a potential view for a long 
time because skin is easy to access with large surface 
area and the route is non invasive. This route of drug 
delivery has gained popularity due to some advantages 
like, it avoids first pass effects, gastrointestinal 
irritation, and metabolic degradation associated with 
oral administration
1,2
.  
Gels are a relatively newer class of drug delivery 
systems constituting large amounts of aqueous or hydro 
alcoholic liquid in a complex network of solid 
particles.  Topical gel formulations provide suitable 
delivery system for drugs because they are less greasy 
and can be easily removed from the skin
3
. They are 
intended to be applied to the skin or certain mucous 
membranes for protective, prophylactic or therapeutic 
purposes.  They embrace a higher aqueous component 
that assists in dissolution of drugs, and facilitate easy 
drug release through the vehicle that is essentially a 
liquid
4
. Despite many advantages some limitations are 
associated with gels, major drawback remains, which is 
its ability to deliver hydrophobic drugs. To overcome 
this limitation, emulgel have been emerged as an 
effective delivery system aiding the incorporation of 
hydrophobic drugs in gel dosage forms. When gels and 
emulsions are utilized in combination, the dosage 
forms are referred as emulgel
5
.  Emulgel is emerging 
field for the topical drug delivery, and till date it has 
less marketed product, so it is interesting and 
challenging to focus on emulgel
6
. Emulgel is the 
approach using the benefits of both emulsion and gels, 
gaining the dual controlled release effect where the 
emulsion either oil in water or water in oil is gelled by 
incorporation in the gel base, simply the emulgel are 
emulsion in gel. Emulgel possess the properties as 
thixotropic, grease less, easily spreadable, easily 
removable, emollient, non staining, water soluble, long 
shelf life, bio friendly and pleasing appearance that 
improves the patient acceptability
7
. 
Etoricoxib is a Non steroidal Anti-Inflammatory Drug 
(NSAID) belonging to the class of cyclooxygenase 2 
(COX-2) inhibitors used in the treatment of relieving 
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moderate pain and swelling of joints associated with 
different forms of arthritis
8
. Clinical trials have 
established the efficacy of etoricoxib in osteoarthritis, 
rheumatoid arthritis, acute gouty arthritis, low back 
pain, acute postoperative pain, and primary 
dysmenorrheal
9
.  
It's very low aqueous solubility and poor dissolution 
can cause formulation problems and limit its 
therapeutic application by delaying the rate of 
absorption and the onset of action by oral route. 
Moreover, oral treatment is associated with greater 
chance of adverse effects or therapeutic failure and 
large amount of drug is lost in the vicinity of the target 
organ. Also oral administration of etoricoxib causes 
gastro-intestinal irritation
10
.  
In the present study, an attempt has been made to 
develop emulgel formulations of etoricoxib so as to 
reduce the side effects of oral administration and to 
enhance percutaneous absorption. 
The selected formulations were further characterized 
for anti-inflammatory activity and compared with 
standard market product Indomethacin. 
 
MATERIALS AND METHODS 
Etoricoxib was obtained from Abumec 
Pharmaceuticals Ltd, Kaduna. Carbopol 934, HPMC 
K4M and Light Liquid paraffin Adler Products 
Limited, Lagos. Tween 20, Span 20 and Propylene 
glycol were obtained from Agary Pharmaceutical 
Limited, Lagos. Methyl paraben was obtained from 
Bentos Pharmaceutical Products Limited, Oyo state, 
Nigeria. 
All other ingredients used were of analytical grade. 
Preparation of Etoricoxib emulgel 
The methods used to prepare etoricoxib emulgel was 
followed as used by Yadav et al. in a previous study
11
. 
By dispersing carbopol and HPMCK4M in purified 
water with constant stirring at a moderate speed gels in 
formulations were prepared. By the means of tri-
ethanol amine pH are adjusted to around 6. Aqueous 
phase was prepared by dissolving Tween 20 in purified 
water while the oil phase of the emulsion was prepared 
by dissolving Span 20 in light liquid paraffin. Methyl 
paraben was dissolved in propylene glycol whereas 
drug was dissolved in ethanol and both solutions were 
mixed with the aqueous phase. Both the oily and 
aqueous phases were separately heated to 70° to 80°C; 
then the oily phase were added to the aqueous phase 
with continuous stirring until cooled to room 
temperature. Finally the emulgel was prepared by 
mixing the both gel and emulsion in 1:1 ratio. The 
composition of different formulations is shown in 
Table 1. 
 
EVALUATION OF EMULGEL FORMULATIONS 
Physical Examination 
The prepared etoricoxib emulgel formulations were 
inspected visually for their colour, homogeneity, 
consistency, grittiness and phase separation. The 
evaluation of the developed formulations for clarity 
observed visually with naked eye. Smears of gels were 
prepared on glass slides and observed under a 
compound microscope for the presence of any 
insoluble particles or grittiness
12
. 
pH 
The pH of the sample was measured by a digital pH 
meter (New Heights Pharmaceuticals ltd, Nigeria) at 
room temperature. The electrode was dipped in gel for 
10 seconds, and the value was read on the digital 
interface
13
. 
Extrudability 
It is an empirical test to measure the force required to 
extrude the material from tube. In the current study, the 
method adopted for extrudability is based upon the 
quantity of etoricoxib emulgel and quantity extruded 
from lacquered aluminium collapsible tube on 
application of weight in grams required to extrude at 
least 0.5 cm ribbon of emulgel in 10 seconds. More the 
quantity extruded, better is extrudability
14,15
. 
Viscosity 
The viscosity of formulated etoricoxib emulgel was 
determined using Brookfield viscometer (Cinthex 
Pharmaceoutical Limited, Nigeria) with spindle no. 18 
at 100 rpm at 25±0.5°C
16
. 
Drug content 
The drug content of etoricoxib emulgel was measured 
by dissolving a known weight of the emulgel 
formulation (one gram) in 100 ml methanol, 
appropriate dilutions were made and the resulting 
solution was then filtering using millipore filter (0.45 
μm). Absorbance was measured at 275 nm using 
UVspectrophotometer (Shimadzu UV 1800). Drug 
content was calculated using the slope and the intercept 
obtained by linear regression analysis of standard 
calibration curve
17
. 
Skin irritation test  
A set of 4 rats was used in the study. A 0.5 gm of 
etoricoxib emulgel formulation was applied on the 
properly shaven area of skin approximately 2.54x2.54 
cm
2
. When the undesirable changes like skin color; 
change in skin morphology was checked for a period of 
24 hr
18
. 
In-vitro diﬀusion study 
The in-vitro diﬀusion study of prepared gel was carried 
out in Keshary Chein diﬀusion cell apparatus. In 
Keshary-Chein diﬀusion cell, 500 mg of etoricoxib 
emulgel was spread uniformly on the cellophane 
membrane which was previously soaked in phosphate 
buﬀer pH 5.5 for 24 h and was sandwiched between 
donor and receptor compartment. 6 ml of phosphate 
buﬀer was used as receptor compartment. The 
temperature was maintained at 37±0.5°C. The whole 
assembly was fixed on a magnetic stirrer and the 
solution in the receptor compartment was constantly 
stirred using magnetic bead at 450 rpm. Sample of 1 ml 
was withdrawn and replacement was done with 1 ml of 
fresh buﬀer. The drug concentration on the receptor 
ﬂuid was determined spectrophotometrically against 
blank at 275 nm. The cumulative amount of drug 
released expressed in % was plotted for 
formulation
19,20
. 
Anti-inflammatory study 
Healthy albino rats of either sex (Wistar strain) 
weighing 150-200 g were used in current study. The 
animals were kept in plastic cages with soft bedding, 6 
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per cage with free access to food and water and were 
maintained under controlled temperature (27±2
0
C) and 
12 hrs: 12 hrs light and dark cycle. Prior to the 
experiment, food was withdrawn overnight but 
adequate water was provided to the rats
21
.  
The animals were divided into two groups of 6 animals 
each. Standard group was treated with indomethacin 
given by I.P., test group receive 2 g etoricoxib emulgel 
formulations of batch EG1 were applied over 9 cm
2 
as 
transdermal patch on the dorsal skin after removing the 
hair with a clipper. The area of application was 
occluded with bandages and it was left in place for 2 
hrs. The dressing was then removed and the emulgel 
remaining on the surface was wiped off with cotton. 
The animals were then injected with 0.1 ml of 1% 
carrageenan solution in saline in plantar region of left 
hind paw and the paw volume was measured after 1, 2, 
4, 6, 8 hr using water plethysmometer. The right hind 
paw served as a reference non inflamed paw for 
comparison. 
Paw volume: Initial Rat paw volume was measured 
using plethysmometer. The paw was marked with ink 
at the level of lateral malleolus and immersed in 
mercury up to the mark in the plethysmometer
22
. Mean 
changes in paw volume were calculated and % 
inhibition of paw edema was calculated using formula:  
% Inhibition =
Vc−  Vt 
Vc 
× 100 
Where, Vc is mean changes in paw volume of control 
group and Vt is mean changes in paw volume treated 
group.                                                                                                   
Paw thickness: Paw thickness was measured by 
compressing the joint by rotating the screw of 
micrometer screw gauge till the pain elicited as 
indicated by squeaking or leg withdrawal
23
. The 
distance moved by the screw gauge was recorded and 
% inhibition of paw thickness was calculated using 
formula:  
% Inhibition =
Tc−  Tt 
Tc 
× 100 
Where, Tc is mean change in paw thickness of arthritis 
control group and Tt is mean changes in paw thickness 
of treated group. 
Statistical  analysis: Data was  expressed  as mean± 
SD and analyzed for statistical significance using 
Student’s  t  test,  one-way  analysis  of  variance 
(ANOVA)  followed  by Dunnett’s  test  or  two-way 
ANOVA followed by Bonferroni test. P<0.05, p<0.01 
and p<0.001 was considered to be significant. 
 
RESULTS AND DISCUSSION 
The objective of the present study was to design and 
characterize an effective topical drug delivery of 
etoricoxib.  Due to its low aqueous solubility and poor 
dissolution it is a poor candidate for oral route.  Thus a 
unique approach of formulating hydrophobic drugs, 
emulgel, where emulsions could be easily incorporated 
into gels was attempted. The solubility of hydrophobic 
drugs can be improved by incorporating them into 
emulsion form, which further helps in enhancing their 
skin permeability. 
In current study 6 emulgel formulations of etoricoxib 
were were successfully formulated using the gelling 
agent like Carbopol 934 and HPMCK4M with 
emulsifiers like Span 20 and  Tween 20 developed and 
evaluated on different parameters. 
The results of physicochemical parameters i.e pH, 
viscosity, extrudability and drug content of all batches 
are shown in Table 2.  All trials of emulgel were found 
to be homogeneous and smears were transparent 
without grittiness or presence of any particles. The pH 
values of emulgel batches were found in the range of 
6.8-7.1 which is similar to skin pH. Viscosity is an 
important parameter for characterizing the emulgels as 
it affects the extrudability and release of drug. The 
viscosity range observed for all formulation was 
12208-12800 cps.  
Extrusion of the emulgel from the tube is an important 
during application and for the patient compliance. 
Emulgels with high consistency may not extrude from 
the tube easily, where as low viscous gel may show 
quickly extrudabilty of emulgels. The extrudability of 
all formulations was found to be satisfactory. The 
percentage drug content of all formulations was found 
to be satisfactory and in the range of 93.54±0.52-
98.74±0.08%. 
The allergic symptoms like inflammation, redness, 
irritation, erythema and edema are not appeared on rats 
up to 24hr. The in vitro drug release profiles of 
etoricoxib emulgel formulations are shown in Figure 1. 
Maximum drug release was observed was 80.82% for 
emulgel formulations of batch EG1 at the end of 210 
min and minimum release 54.62% was shown by batch 
EG3. Drug release kinetics data of the emulgels is 
given in Table 3. 
Local injection of carrageenan into rat hind paw 
induces acute inflammatory responses such as edema. 
The development of the edema induced by carrageenan 
has been described as a biphasic event
22
. A rapid early 
phase (up to 2 h) is triggered by the concerted release 
of histamine, bradykinin, 5-hydroxytryptamine or 
cyclooxygenase products. And a more sustained late 
phase (2 to 5 h) is regulated by neutrophil infiltration 
and sustained production of arachidonic metabolites 
(prostanoids) (primarily by cyclooxygenase) or nitric 
oxide from inducible nitric oxide synthase
23
. Standard 
indomethacin shows 54.861% mean paw volume 
percentage inhibition, while emulgel formulation of 
batch EG1 shows 18.59% (Table 4).  
In a previous study Prakash et al. has evaluated topical 
etoricoxib gel for anti-inflammatory study for 6 hrs. 
Current study checked this study for 8 hrs to observe 
the changes for a longer duration
24
.  
Mean percentage inhibition of paw thickness by 
indomethacin was found to be 29.91%, while EG1 
shows 18.986% (Table 5). 
 
CONCLUSION 
At present scenario, emulgel is one of the recent 
technologies used for dual control release of emulsion 
and gel for topical use. Moreover, they will become a 
solution for loading hydrophobic drugs in water soluble 
gel bases for the long term stability. The stability of 
emulsion is increased, when it is incorporated into gel. 
Etoricoxib is a hydrophobic drug. In current study 
Etoricoxib was successfully formulated in an emulgel 
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drug delivery with gelling agent like Carbopol 934 and 
HPMCK4M with emulsifiers like Span 20 and  Tween 
20 developed with simple, commercial feasible 
manufacturing process.  
Etoricoxib emulgel formulation EG1 used in this study 
showed significant reduction of paw edema thickness 
and volume at 8 hrs or more after carrageenan 
injection, demonstrated that the emulgel possess fairly 
good anti-inflammatory activity. 
Based on different evaluation parameters, study 
concludes that EG1 emulgel formulation was the 
optimum formulations. However, in vivo investigation 
in relevant animal models may provide further insights 
into the efficiency of this drug delivery system and its 
relevance, which inevitably warrants further research. 
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Table 1: Quantative composition of etoricoxib emulgel formulations 
Ingredients 
(%w/w)  
EG1 EG2 EG3  EG4  EG5  EG6  
Etoricoxib 1  1  1  1  1  1  
Carbopol 934  1  1  1  -  -  -  
HPMC K4M 1 1.5  2 -  -  -  
Xanthan Gum  -  -  -  1  1  1  
Light Liquid 
paraffin  
7.5  5  7.5  5  7.5  5  
Tween 20  0.6  1  1  -  -  -  
Span 20 -  -  -  0.6  1  1  
Propylene glycol  7  7  7  7  7  7  
Ethanol  10  10  10  10  10  10  
Methyl paraben  0.03  0.03  0.03  0.03  0.03  0.03  
Purified water q.s.  100  100  100  100  100  100  
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Table 2: Physicochemical characterization of etoricoxib emulgel 
Formulation 
Code 
Parameters 
Nature pH 
Viscosity 
(cps) 
Spreadability 
gm cm/sec 
Drug 
content 
(%w/w) 
Extrudability 
 
EG1 
White, 
Homogenous 
6.8 12208 17.8±0.18 96.25±0.09 ++ 
EG2 
White, 
Homogenous 
6.9 12510 25.4±0.09 98.36±0.15 +++ 
EG3 
White, 
Homogenous 
7.1 12415 27.1±0.44 95.23±0.22 ++ 
EG4 
White, 
Homogenous 
7.0 12522 29.5±0.21 94.67±0.18 +++ 
EG5 
White, 
Homogenous 
6.8 12800 28.4±0.27 93.54±0.52 ++ 
EG6 
White, 
Homogenous 
7.0 12648 32.6±0.15 98.74±0.08 +++ 
Excellent +++, Good++, Satisfactory+ 
 
 
Figure 1: In-vitro diffusion profile of etoricoxib  emulgel formulations 
 
Table 3: Drug release kinetic parameters for different etoricoxib emulgel formulations 
Batch 
Code 
Zero order model First order model Higuchi model Higuchi model  Korsmeyer-Peppas model 
R K R K R K Slope(n) R K 
EG1 0.8976 3.6372 0.9555 -0.0549 0.9846 10.3551 0.6248 0.9981 7.8464 
EG2 0.9682 2.6368 0.9562 -0.0358 0.9783 8.8968 0.7077 0.9977 4.7338 
EG3 0.9657 2.0245 0.9581 -0.0252 0.9274 10.3922 0.8265 0.9946 2.8082 
EG4 0.8561 4.2172 0.9345 -0.0783 0.9758 8.9453 0.5721 0.9984 11.5966 
EG5 0.9345 2.6465 0.9548 -0.036 0.9368 10.4181 0.6184 0.9937 7.1578 
EG6 0.9621 2.0239 0.9563 -0.0292 0.9682 8.6137 0.7018 0.9954 4.5348 
 
 
Figure 2:  Stability study of etoricoxib emulgel formulation of batch EG1 
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Table 4:  % Inhibition on carrageenan induced paw volume by different treatment 
Treatment Percent inhibition of paw oedema Mean of % 
Inhibition 
 1 hr 2hr 4hr 6hr 8hr  
Standard (10mg/kg, 
I.P. Indomethacin) 
12.87 21.39 31.79 39.41 47.83 54.86 
Etoricoxib emulgel, 
EG1, 2 gm 
4.20 5.12 6.06 11.07 13.51 18.597 
N = 6, p < 0.05 
 
 
 
Table 5:  % Inhibition on carrageenan induced paw thickness by different treatment 
Treatment Percent inhibition of paw thickness 
 
Mean of % 
Inhibition 
 1 hr 2hr 4hr 6hr 8hr  
Standard (10mg/kg, 
I.P. Indomethacin) 
15.08 18.89 22.61 25.23 27.74 29.91 
Etoricoxib emulgel, 
EG1, 2 gm 
3.19 5.42 11.37 14.13 16.81 18.98 
N = 6, p< 0.05 
 
 
 
 
Figure 3: Mean % paw volume and thickness inhibition 
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